Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Darapladib

Next Previous
X
Search
Drug Profile

Darapladib

Alternative Names: 480848; SB-480848

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Human Genome Sciences
  • Developer GlaxoSmithKline
  • Class Acetamides; Fluorobenzenes; Pyrimidinones; Small molecules; Sulfides
  • Mechanism of Action 1-alkyl-2-acetylglycerophosphocholine esterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Atherosclerosis; Diabetic macular oedema

Most Recent Events

  • 12 Nov 2016 Adverse events data from the phase III SOLID-TIMI 52 trial in Atherosclerosis presented at the 89th Annual Scientific Sessions of the American Heart Association
  • 01 Aug 2014 GlaxoSmithKline completes a phase I pharmacodynamic trial in Atherosclerosis (in patients with Type-2 diabetes mellitus) in United Kingdom (NCT02058641)
  • 30 Jun 2014 Discontinued - Phase-III for Atherosclerosis in South Korea, Japan, Norway, India, Hong Kong, Ukraine, Russia, Thailand, New Zealand, Taiwan, Pakistan, Philippines, Turkey, Israel, Colombia, Peru, Chile, Brazil, Mexico, Germany, France, Denmark, Czech Republic, Bulgaria, Belgium, Canada, Romania, Poland, the Netherlands, Italy, Hungary, South Africa, Sweden, Spain, Slovakia, Australia, Estonia, Greece, United Kingdom, China, Argentina and USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top